[go: up one dir, main page]

MX2019011610A - Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta. - Google Patents

Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.

Info

Publication number
MX2019011610A
MX2019011610A MX2019011610A MX2019011610A MX2019011610A MX 2019011610 A MX2019011610 A MX 2019011610A MX 2019011610 A MX2019011610 A MX 2019011610A MX 2019011610 A MX2019011610 A MX 2019011610A MX 2019011610 A MX2019011610 A MX 2019011610A
Authority
MX
Mexico
Prior art keywords
inhibitors
derivatives
quinoxaline
pyridoprazine
pi3k
Prior art date
Application number
MX2019011610A
Other languages
English (en)
Other versions
MX391942B (es
Inventor
René Angibaud Patrick
Meerpoel Lieven
Alexis Georges Querolle Olivier
Meyer Christophe
Jean-Claude Berthelot Didier
Philippe Victor WILLOT Matthieu
Fran¿ois Alain Jean JOUSSEAUME Thierry
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019011610A publication Critical patent/MX2019011610A/es
Publication of MX391942B publication Critical patent/MX391942B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invencion se refiere a derivados de quinoxalina y piridopirazina sustituidos de Formula (I) (ver formula) en donde las variables tienen el significado definido en las reivindicaciones; los compuestos de acuerdo con la presente invencion son utiles como inhibidores de pI3Kß; la invencion se refiere ademas a composiciones farmaceuticas que comprenden dichos compuestos como principio activo, asi como tambien al uso de dichos compuestos como un medicamento.
MX2019011610A 2017-03-29 2018-03-29 Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta MX391942B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17163625 2017-03-29
PCT/EP2018/058175 WO2018178280A1 (en) 2017-03-29 2018-03-29 Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors

Publications (2)

Publication Number Publication Date
MX2019011610A true MX2019011610A (es) 2019-11-08
MX391942B MX391942B (es) 2025-03-21

Family

ID=58454972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011610A MX391942B (es) 2017-03-29 2018-03-29 Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta

Country Status (13)

Country Link
US (1) US11130751B2 (es)
EP (1) EP3601254B1 (es)
JP (1) JP7053654B2 (es)
KR (1) KR20190133729A (es)
CN (1) CN110461827A (es)
AU (1) AU2018246321B2 (es)
BR (1) BR112019020309A2 (es)
CA (1) CA3054107A1 (es)
EA (1) EA201992296A1 (es)
ES (1) ES2925176T3 (es)
IL (1) IL269598B (es)
MX (1) MX391942B (es)
WO (1) WO2018178280A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024272375A1 (en) * 2023-05-12 2026-01-08 Mirati Therapeutics, Inc. Substituted quinoxalines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103756A2 (en) 2006-03-02 2007-09-13 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
ES2647163T3 (es) 2008-01-04 2017-12-19 Intellikine, Inc. Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K
KR20110114663A (ko) 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
AU2010226490A1 (en) 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
US8569296B2 (en) 2009-09-29 2013-10-29 Xcovery Holding Company, Llc PI3K (delta) selective inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
CN103124496B (zh) 2010-10-06 2016-03-30 葛兰素史密丝克莱恩有限责任公司 作为pi3激酶抑制剂的苯并咪唑衍生物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
WO2013095761A1 (en) 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
EA028722B1 (ru) 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
CN106831722B (zh) 2013-10-16 2019-08-30 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
HRP20191550T1 (hr) 2014-12-19 2019-11-29 Janssen Pharmaceutica Nv Derivati imidazopiridazina kao inhibitori pi3kbeta
CA2967546A1 (en) 2014-12-19 2016-06-23 Janssen Pharmaceutica Nv Heterocyclyl linked imidazopyridazine derivatives as pi3k.beta. inhibitors
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
WO2017060406A1 (en) * 2015-10-09 2017-04-13 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors

Also Published As

Publication number Publication date
BR112019020309A2 (pt) 2020-04-28
MX391942B (es) 2025-03-21
AU2018246321A1 (en) 2019-11-14
EA201992296A1 (ru) 2020-02-12
EP3601254A1 (en) 2020-02-05
KR20190133729A (ko) 2019-12-03
JP2020512352A (ja) 2020-04-23
IL269598A (en) 2019-11-28
JP7053654B2 (ja) 2022-04-12
CN110461827A (zh) 2019-11-15
CA3054107A1 (en) 2018-10-04
AU2018246321B2 (en) 2021-07-29
ES2925176T3 (es) 2022-10-14
IL269598B (en) 2022-08-01
US11130751B2 (en) 2021-09-28
EP3601254B1 (en) 2022-05-25
WO2018178280A1 (en) 2018-10-04
US20200181132A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
ECSP17073965A (es) Derivados de ciclohexano sustituido con amido
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UY35237A (es) Composiciones que comprenden un compuesto de triazol
UY35238A (es) Composiciones que comprenden un compuesto de triazol
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
CR20150440A (es) Nuevos derivados de piridina
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2019011610A (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.
MX375485B (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta